This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

IgA Nephropathy, Lymphocyte Homing and IgA Class Switch (NIDOCIGA)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Limoges Identifier:
First received: January 18, 2013
Last updated: August 19, 2016
Last verified: November 2012

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN.

Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.

Condition Intervention
IgA Nephropathy Other: blood test

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: IgA Nephropathy, Lymphocyte Homing and IgA Class Switch

Resource links provided by NLM:

Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization. [ Time Frame: 30 minutes ]

Secondary Outcome Measures:
  • The secondary outcome measure is the level of expression of the homing molecules in lymphocytes B IgA memory [ Time Frame: 30 minutes ]

Enrollment: 72
Study Start Date: February 2013
Study Completion Date: June 2016
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
blood test Other: blood test


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age > 18 and < 70 years
  • IgA nephropathy documented by the kidney biopsy in the six months preceding the inclusion
  • Glomerular filtration rate (MDRD formula as simplified) < 90 ml/mn and > 30 ml/mn/1,73 m2
  • Consent form signed

Exclusion Criteria:

  • Patients with cirrhosis or chronic liver disease
  • Patients with a history of Crohn's disease or celiac disease
  • Patients who received treatment with corticosteroids or affiliates for six months
  • Patients who received a live attenuated vaccine during the past 4 weeks
  • Patients with a known infection such as HIV, hepatitis B or C
  • Patients who presented with a serious infection during the last month
  • Breastfeeding women
  • Patients not affiliated with a social security scheme
  • Under guardianship patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01775527

University Hospital, Limoges
Limoges, France, 87 042
Sponsors and Collaborators
University Hospital, Limoges
Principal Investigator: Ahmed Boumediene, doctor University Hospital, Limoges
  More Information

Responsible Party: University Hospital, Limoges Identifier: NCT01775527     History of Changes
Other Study ID Numbers: I10 014
Study First Received: January 18, 2013
Last Updated: August 19, 2016

Additional relevant MeSH terms:
Kidney Diseases
Glomerulonephritis, IGA
Urologic Diseases
Autoimmune Diseases
Immune System Diseases processed this record on August 16, 2017